News FocusCancer Research

Looking for a Target On Every Tumor

Science  09 Oct 2009:
Vol. 326, Issue 5950, pp. 218-220
DOI: 10.1126/science.326_218

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


This article has a correction. Please see:

Summary

A handful of major U.S. cancer centers are laying plans to analyze the tumors of every lung cancer patient who comes in the door and check for an array of mutations. The aim is to match patients with a drug that goes after the tumor's genetic weak spot. Proponents hope that comprehensive tumor genetic testing will soon become a standard part of a patient's medical record. The grim reality, however, is that even when a match is found, the new targeted drugs have mainly slowed tumors, not stopped them in advanced lung cancer.

Related Content